U.S. regulators have publicly rebuked drugmaker Lundbeck over the way it marketed one of its migraine treatments online.
According to Endpoints News, the Food and Drug Administration criticized Lundbeck Seattle Biopharmaceuticals for two promotional webpages tied to the migraine drug. The FDA's objection, as reported by Endpoints, was that the pages made allegedly inflated claims about how well the drug actually works.
By the time the criticism surfaced, the pages were already gone. Endpoints News reports that neither of the two webpages is still online.
The FDA polices how pharmaceutical companies advertise their products, and drugmakers are required to keep promotional claims consistent with what a drug's clinical evidence supports. When a company overstates a treatment's effectiveness, regulators can push back — as appears to have happened here. The source item does not specify which migraine drug was involved, what specific claims the FDA flagged, or what penalties, if any, the company faces.
Lundbeck's response, the exact language of the disputed claims, and the FDA's full reasoning are not detailed in the available reporting.
Why it matters: For patients and prescribers, marketing that overstates a drug's benefits can shape treatment decisions on shaky ground, which is why regulators scrutinize how medicines are advertised — even on pages a company later quietly takes down.